Eevia Health appoints a Shareholders' Nomination Committee
Eevia Health Plc, ("Eevia" or "The Company") has appointed a Shareholders' Nomination Committee
The following members have been appointed to Eevia's Shareholders' Nomination Committee: Joel Westerström, Partner at Partner Fondkommission AB; Tuomas Lehtimäki, Partner at Smartius Law Firm; Martin Bjørklund, Chairman of the Company's Board of Directors.
The nomination is in line with a decision taken by the Annual General Meeting (AGM) held on 22 June 2021. However, the process of establishing the Nomination Committee has taken longer than originally anticipated. As such, in order to be pragmatic during this first year, the board has decided to simplify the committee for the current period. As such, we have limited the number of members to three. We anticipate increasing the number of members to four next year. The Nomination Committee is responsible for drafting and presenting proposals covering the remuneration and number of members of the Board of Directors and for presenting candidates as potential Board members to the AGM. The Nomination Committee will forward its proposals for the AGM to the Board of Directors in time for them to be included in the invitation to the meeting sent out to shareholders.
Eevia Health Plc
Gabriella Beni
CFO
For further information, please contact:
Martin Bjørklund
Eevia Health Plc Chair of the Board of Directors
Telephone: +47 48 40 51 97
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product; Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, Chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. The factory operates near the raw material harvest areas. A uniquely short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.
Om Eevia Health
Eevia Health targets health problems with bioactive extracts from plant material. The human body has an incredible ability to restore good health. However, sometimes the body needs active support. Our mission is to support good health and well-being with plant extracts which have scientifically documented health benefits. Eevia Health manufactures and markets organic ingredients from abundant plant material in the Arctic. Our products are targeted against low-grade inflammation, problems in eye and brain health, and metabolic effects. We collaborate with scientists in Finland and abroad to scientifically substantiate the positive effects of ingredients and also to document the safety of use.
